Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DaxibotulinumtoxinA 20 units Clear all
Terminated Phase 3 Interventional

Refractory Urge Incontinence and Botox Injections

NCT00373789
View directory record Official record
Conditions
Urinary Incontinence, Detrusor Overactivity, Urinary Urgency, Urge Urinary Incontinence
Interventions
Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 17, 2026, 5:33 AM EDT
Withdrawn Phase 4 Interventional

The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder

NCT05393921
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Intravesical Botox injection
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Cleveland, Ohio • Lyndhurst, Ohio • Richmond Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome

NCT02070302
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Benjamin Sucher
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

H-22411: BOTOX® for Peyronie's Disease

NCT00812838
View directory record Official record
Conditions
Peyronie's Disease
Interventions
100 units of Botulinum Toxin Type A, Preservative free normal saline, 100 units Botulinum Toxin A
Drug · Other
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 17, 2026, 5:33 AM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Sep 17, 2026, 5:33 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder

NCT04020510
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 17, 2026, 5:33 AM EDT
Not listed Not applicable Interventional

Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain

NCT01905137
View directory record Official record
Conditions
Myofascial Pelvic Pain
Interventions
Intervention-Botulinum Toxin Type A, placebo
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

NCT03985982
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Brow Lifting With Dysport

NCT01401803
View directory record Official record
Conditions
Brow Ptosis, Lid Ptosis
Interventions
Dysport
Drug
Lead sponsor
Kenneth Beer
Individual
Eligibility
25 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

DaxibotulinimtoxinA for Treatment of Platysmal Neck Bands

NCT06225492
View directory record Official record
Conditions
Aging
Interventions
DaxibotulinumtoxinA 15 units, DaxibotulinumtoxinA 20 units
Drug
Lead sponsor
Main Line Center for Laser Surgery
Other
Eligibility
31 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 17, 2026, 5:33 AM EDT
Terminated Phase 3 Interventional Results available

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

NCT02097121
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive
Interventions
BOTOX®
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
8
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 17, 2026, 5:33 AM EDT
Not listed Phase 4 Interventional

BOTOX® at the Time of Prolapse Surgery for OAB

NCT04807920
View directory record Official record
Conditions
Urinary Bladder, Overactive, Pelvic Organ Prolapse
Interventions
OnabotulinumtoxinA 100 UNT, Injectable saline
Drug · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 2 Interventional

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

NCT04401176
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 17, 2026, 5:33 AM EDT
Recruiting Phase 4 Interventional

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

NCT04305743
View directory record Official record
Conditions
Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
Interventions
OnabotulinumtoxinA 100 UNT
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Upper Facial Remodeling With Perlane-L and Dysport

NCT01354743
View directory record Official record
Conditions
Mild to Moderate Temporal Atrophy, Moderate to Severe Glabellar Rhytids, Moderate to Severe Periorbital Rhytids
Interventions
Dysport, Perlane L
Drug · Device
Lead sponsor
Beer, Kenneth R., M.D., PA
Individual
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Results available

Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?

NCT04124939
View directory record Official record
Conditions
Overactive Bladder
Interventions
OnabotulinumtoxinA 100 Units
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Greensboro, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

NCT00770029
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Meatrie, Louisiana • Chestnut Hill, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Functional Effects of Botox on the Brain Using MRS and fMRI

NCT03373162
View directory record Official record
Conditions
Healthy
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A

NCT05466539
View directory record Official record
Conditions
Compartment Syndrome of Leg
Interventions
AbobotulinumtoxinA, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Brookhaven, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Not applicable Interventional Results available

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

NCT06059066
View directory record Official record
Conditions
Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Interventions
Standard number of injection sites, Reduced number of injection sites
Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

NCT02165111
View directory record Official record
Conditions
Scleroderma, Raynaud's Syndrome
Interventions
Onabotulinumtoxin A, sterile saline solution
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 17, 2026, 5:33 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

"Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome"

NCT03616262
View directory record Official record
Conditions
Complex Regional Pain Syndrome
Interventions
Botox + Lidocaine, Lidocaine alone
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 2Phase 3 Interventional

The Efficacy of Botulinum Toxin vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis

NCT05367271
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Botulinum Toxin A, Dexamethasone
Drug
Lead sponsor
Western Institute for Veterans Research
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 17, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

NCT00512135
View directory record Official record
Conditions
Glabellar Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 units)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Los Angeles, California • Englewood, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 17, 2026, 5:33 AM EDT